APLT News and Press, Applied Therapeutics Inc. From 04/15/24

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the appointment of Dale ...

2024-04-07 03:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-05 16:42:08 ET Gainers: Applied Optoelectronics ( AAOI ) +4% . Outset Medical ( OM ) +2% . SunPower Corporation ( SPWR ) +2% . Applied Therapeutics ( APLT ) +2% . Enovix Corporation ( ENVX ) +2% . Losers: Palladyn...

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present ful...

2024-03-28 17:01:46 ET More on Applied Therapeutics Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible Applied Therapeutics: Update Following Failure In Diabetic Cardiomyopathy (Downgrade) ARISE-HF Phase 3 Trial Likely To Disappoint Due To...

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and D...

2024-03-22 16:43:28 ET More on Applied Therapeutics Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible Applied Therapeutics: Update Following Failure In Diabetic Cardiomyopathy (Downgrade) Read the full article on Seeking Alpha For...

2024-03-06 07:31:25 ET More on Applied Therapeutics Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible Applied Therapeutics: Update Following Failure In Diabetic Cardiomyopathy (Downgrade) ARISE-HF Phase 3 Trial Likely To Disappoint Due To...

NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in 4Q 2024 Announced positive results from 12-month interim analysis of govorestat in o...

2024-02-28 10:12:47 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Coupang (NYSE: CPNG ) stock is on the rise Wednesday following the release of the e-commerce company’s earnings report for the fourth quarter of 2023 . The good news ...